Thursday, February 28, 2013
Vancouver-based Neovasc said the clinical protocol for its COSIRA (coronary sinus reducer for treatment of refractory angina) trial has been published in the peer-reviewed journal Trials. COSIRA is a double-blind, randomized, multi-center trial further assessing the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina. The COSIRA trial is currently enrolling patients in the U.K., Europe and Canada.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) it has completed and surpassed the $50 million Brin Wojcicki Challenge. Longtime foundation supporters Sergey Brin and Anne Wojcicki have matched more than $53 million in capacity-building gifts received by MJFF from January 1, 2011, to December 31, 2012.